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ABSTRACT
Objectives Digital ulcers (DUs) occur in up to half of
patients with systemic sclerosis (SSc) and may lead to
infection, gangrene and amputation with functional
disability and reduced quality of life. This study has
elucidated the burden of SSc-associated DUs through
identiﬁcation of four patient categories based on the
pattern of DU recurrence over a 2-year observation
period.
Methods Patients with SSc-associated DUs enrolled in
the Digital Ulcers Outcome Registry between 1 April
2008 and 19 November 2013, and with ≥2 years of
observation and ≥3 follow-up visits during the
observation period were analysed. Incident DU-
associated complications were recorded during follow-up.
Work and daily activity impairment were measured using
a functional assessment questionnaire completed by
patients after the observation period. Potential factors
that could predict incident complications were identiﬁed
in patients with chronic DUs.
Results From 1459 patients, four DU occurrence
categories were identiﬁed: 33.2% no-DU; 9.4%
episodic; 46.2% recurrent; 11.2% chronic. During the
observation period, patients from the chronic category
had the highest rate of incident complications, highest
work impairment and greatest need for help compared
with the other categories. Independent factors associated
with incident complications included gastrointestinal
manifestations (OR 3.73, p=0.03) and previous soft
tissue infection (OR 5.86, p=0.01).
Conclusions This proposed novel categorisation of
patients with SSc-associated DUs based on the
occurrence of DUs over time may help to identify
patients in the clinic with a heavier DU burden who
could beneﬁt from more complex management to
improve their functioning and quality of life.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic, heterogeneous
connective tissue disease that is characterised by
small vessel vasculopathy, autoantibody production
and ﬁbroblast dysfunction,1 leading to increased
deposition of extracellular matrix and ﬁbrosis.2
Raynaud’s phenomenon and hardening of the skin
(scleroderma) are hallmarks of the disease.1 The
clinical presentation of SSc varies, with symptoms
presenting in the skin, cardiovascular, gastrointes-
tinal (GI), musculoskeletal and pulmonary systems.1
Digital ulcers (DUs) are a frequent external mani-
festation of vasculopathy in scleroderma3 and occur
in up to half of patients with SSc.4 Data from the
University of Pittsburgh found that, of those patients
who experience a DU, more than half have persistent
or recurrent DUs for at least 6 months.5 Several
studies have shown that DUs are associated with sig-
niﬁcant burden, with complications such as infection,
gangrene and amputation leading to reduced quality
of life (QoL) due to pain and disability,6–8 an
increased frequency of hospitalisation3 and cardio-
vascular worsening and decreased survival.9
Previous studies have proposed various categori-
sations for DUs;10 11 however, their utility in the
clinic has been limited. There is still a need for a
categorisation that enables the physician to deter-
mine patients who are likely to have increased
disease burden and thus need more complex
management.
In order to detail the impact of the burden of
DUs associated with systemic sclerosis (SSc-DUs)
on clinical practice, we reviewed patient data from
the Digital Ulcers Outcome (DUO) Registry. Our
proposed categorisation, based on the longitudinal
pattern of DU recurrence during a 2-year observa-
tion of >1400 patients, may help us to identify
patients with a heavier DU disease burden.
METHODS
Study design and patient population
The DUO Registry was an international, prospect-
ive, observational study that collected data from
European patients with a history of SSc-DUs. It was
initiated on 1 April 2008 to fulﬁl a postmarketing
commitment to the European Medicines Agency
(EMA) by Actelion Pharmaceuticals, following
the approval of bosentan (Tracleer®, Actelion
Pharmaceuticals, Allschwil, Switzerland) for
patients with SSc-DUs.12 Patients with SSc and a
history of DUs, or DUs present at the time of enrol-
ment, were eligible for inclusion in the registry irre-
spective of their treatment regimen; patients
underwent clinical assessment and received treat-
ment and follow-up care as determined by their
physician. For this analysis, the cohort of eligible
patients was required to have ≥2 years of observa-
tion from enrolment and ≥3 follow-up visits during
this time (cohort A) up to the data cut-off of 19
November 2013.
Data collection
Data were collected from the patient’s medical
chart and recorded on an electronic case report
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form (eCRF, data were not available for every ﬁeld for all
patients). The quality assurance process included automatic veri-
ﬁcation in real time such as checking for range and plausibility.
Source data were veriﬁed in 10% of patients once a year.
Data collected at enrolment included patients’ demographic
and clinical characteristics, the presence of antibodies, history of
interventions/complications related to DUs and documentation
of ongoing medications. Data collected through follow-up visits
included the number of ﬁnger DUs, the number of months in
which a new DU occurred, the incidence of complications and
interventions associated with DUs and patients’ self-reported
functional impairment. A DU was deﬁned on the eCRF as a
denuded area with a deﬁned border and loss of epithelialisation,
loss of epidermis, excluding ﬁssures, paronychia, extrusion of
calcium or ulcers over the metacarpophalangeal joints.
Patients’ functional impairment was assessed via a question-
naire that was designed for the DUO Registry and translated
into the local languages of the participating countries. The ques-
tionnaire as described by Guillevin et al13 is a self-reported
evaluation of the extent that ﬁnger ulcers affected the patient’s
ability to work and perform regular daily activities, along with
their need for paid and unpaid help. The analysis reported here
used the questionnaire that was completed at the end of the
2-year observation period (window of 18–27 months). The
recall period was the month prior to completion of the
questionnaire.
Work impairment (determined in employed patients only)
and daily activity impairment were scored by patients on a scale
from 0 (DU-associated problems had no effect) to 10
(DU-associated problems completely prevented the patient’s
ability to carry out that type of activity). Impairment percen-
tages were calculated from the scores for work and daily impair-
ment. Work time missed was expressed as a percentage of actual
hours missed during the past month out of the expected
number of hours normally worked. Overall work impairment
was calculated as the sum of work time missed and lost product-
ivity at work (work time attended multiplied by work impair-
ment percentage). If ‘work hours missed’ was not reported and
‘productivity impairment due to DUs’ was reported, work hours
missed was imputed to 0. If hours of paid or unpaid help were
not reported, but the question whether the patient needed help
was answered, missing hours of either paid or unpaid help were
imputed to 0. The maximum possible number of monthly work
hours and monthly work hours missed was ﬁxed at 42 per week
multiplied by 4.3, based on the longest legal work week in any
European country within the DUO Registry’s remit.
Data analysis
Data were analysed descriptively with the use of counts, propor-
tions, mean, median and 95% CIs. Kaplan–Meier analysis was
used to estimate the survival distribution for time to a new DU
following enrolment. In general, missing values were not
imputed, unless otherwise stated. Analyses were carried out
using SAS® V.9.2 (SAS Institute Inc., Cary, North Carolina, USA).
Based on the DU recurrence pattern during the 2-year obser-
vation period following enrolment, using the number of DUs
recorded at each follow-up visit and the occurrence of new DUs
between visits, patients were divided into four categories: (1)
no-DU, (2) episodic, (3) recurrent and (4) chronic (table 1).
In order to evaluate potential factors that could predict inci-
dent complications in the chronic category, univariable logistic
regression analysis (ULR) was conducted. Incident complications
were deﬁned as the occurrence of at least one of ﬁve complica-
tions during the 2-year observation period: gangrene,
amputation, soft tissue infection requiring systemic antibiotics,
hospitalisation for DUs and use of pain medication. Potential
predictive factors for incident complications were considered
among the patient characteristics recorded at the enrolment visit.
Multivariable logistic regression (MLR) analysis was conducted
using those factors with a p value <0.15 from the univariable
models, considering interdependency among similar factors.
Sensitivity analyses were conducted in order to conﬁrm that
the demographic and clinical characteristics of the patients
included in the cohort used for this analysis (cohort A) were
similar to the other cohorts within the registry: patients with
<2 years follow-up (cohort B); patients with no follow-up visit,
enrolment visit only (cohort C); and patients with ≥2 years
follow-up and <3 follow-up visits (cohort D).
RESULTS
In total, 4534 patients were enrolled in the DUO Registry from
394 centres in 18 European countries (see online supplementary
appendix) up to 19 November 2013. Of these patients, 1459
were eligible for inclusion in this analysis (≥2 years of observa-
tion from enrolment and ≥3 follow-up visits in the ﬁrst 2-year
period; cohort A). Patients included in cohort A were enrolled
from 15 of the 18 countries. The sensitivity analysis conﬁrmed
that the demographic and clinical characteristics of patients in
cohort A were similar to those in other cohorts (see online
supplementary table S1).
Patient demographic and clinical characteristics
Overall, 33.2% of patients were categorised as no-DU, 9.4% as
episodic, 46.2% as recurrent and 11.2% as chronic. The median
number of follow-up visits over the 2-year period was similar in all
categories (4 (no-DU), 4 (episodic), 5 (recurrent) and 4 (chronic)).
Overall, 84–88% of patients had a follow-up visit at 6-months
(±3 months), 84–89% had a follow-up visit at 12-months (±3
months), 78–84% had a follow-up visit at 18 months (±3 months)
and 85–90% had follow-up visit at 24 months (±3 months) across
the four categories. The demographic and clinical characteristics
of patients in the four categories are summarised in table 2.
Patients in all categories were predominantly female. Overall,
the most common SSc manifestations were gastrointestinal (GI)
manifestations and lung ﬁbrosis. Differences were apparent
between each of the categories for many clinical characteristics
and the presence of antibodies. Patients from the chronic cat-
egory had the highest prevalence of lung ﬁbrosis and were
youngest at enrolment, at their ﬁrst Raynaud’s phenomenon and
at their ﬁrst DU compared with the other recurrence categories.
At enrolment, ≥3 DUs were present in 8.9% of patients from
the no-DU category, 14.1% of patients from the episodic cat-
egory, 23.1% of patients from the recurrent category and
53.4% of patients from the chronic category. The chronic
Table 1 Categories based on recurrence of DUs within a 2-year
observation period
Category Definition
No-DU No DU at any FU visit
Episodic Rarely recurrent: only 1 FU visit with either ≥1 DU or new DU; the
remaining FU visits have no DU and no new DU
Recurrent Frequently recurrent: ≥2 FU visits with DU and/or new DU, and ≥1
visit with no DU and no new DU
Chronic ≥1 DU and/or new DU at every FU visit
DU, digital ulcers; FU, follow-up.
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Table 2 Demographic and clinical characteristics of the four recurrence categories
No-DU (n=484) Episodic (n=137) Recurrent (n=674) Chronic (n=164) Total (N=1459)
Gender, n 484 137 674 164 1459
Female, % 80.6 81.8 83.7 88.4 83.0
Age at enrolment, n 484 137 674 164 1459
Mean (SD), years 55.9 (13.2) 54.7 (13.7) 53.2 (14.5) 50.9 (12.4) 54.0 (13.8)
Age at first RP, n 418 121 607 148 1294
Mean (SD), years 43.0 (15.3) 42.9 (15.1) 39.5 (15.6) 35.2 (13.6) 40.4 (15.4)
Age at first DU, n 345 111 555 135 1146
Mean (SD), years 49.5 (14.9) 48.7 (14.5) 46.1 (15.2) 41.7 (14.0) 46.8 (15.1)
SSc classification, n 482 136 667 163 1448
Diffuse SSc, % 29.7 30.1 39.3 46.6 36.0
Limited SSc, % 56.2 58.8 51.3 44.2 52.8
Overlap/mixed CTD, % 8.9 5.1 6.3 7.4 7.2
Other, % 5.2 5.8 3.1 1.8 3.9
Organ manifestations, n 484 137 674 164 1459
GI, % 54.8 52.6 58.2 63.4 57.1
Heart, % 9.7 7.3 8.6 9.8 9.0
Kidney, % 6.4 2.2 3.7 3.7 4.5
Lung fibrosis, % 34.9 38.7 39.8 52.4 39.5
Antibodies, n1/n2 (%)
ACA 165/339 (48.7) 41/98 (41.8) 213/528 (40.3) 34/123 (27.6) 453/1088 (41.6)
ANA 411/438 (93.8) 115/124 (92.7) 592/ 623 (95.0) 154/158 (97.5) 1272/1343 (94.7)
Anti-Scl 70 126/350 (36.0) 53/101 (52.5) 263/567 (46.4) 90/149 (60.4) 532/1167 (45.6)
Anti-U1 RNP 31/239 (13.0) 3/65 (4.6) 32/395 (8.1) 12/99 (12.1) 78/798 (9.8)
Anti-U3 RNP 8/150 (5.3) 0/44 (0.0) 8/254 (3.1) 9/68 (13.2) 25/516 (4.8)
RNA polym III 29/178 (16.3) 3/44 (6.8) 27/276 (9.8) 6/64 (9.4) 65/562 (11.6)
History of previous DU-associated complications/interventions, n1/n2 (%)
Critical digital ischaemia 128/261 (49.0) 36/91 (39.6) 167/380 (43.9) 48/96 (50.0) 379/828 (45.8)
Gangrene 88/444 (19.8) 16/126 (12.7) 157/627 (25.0) 45/155 (29.0) 306/1352 (22.6)
Autoamputation 15/448 (3.3) 7/127 (5.5) 51/629 (8.1) 18/156 (11.5) 91/1360 (6.7)
Soft tissue infection requiring systemic antibiotics 78/420 (18.6) 39/122 (32.0) 209/600 (34.8) 86/149 (57.7) 412/1291 (31.9)
Osteomyelitis 15/438 (3.4) 3/124 (2.4) 22/628 (3.5) 12/153 (7.8) 52/1343 (3.9)
Hospitalisation for DUs 164/444 (36.9) 54/128 (42.2) 298/633 (47.1) 93/155 (60.0) 609/1360 (44.8)
Upper limb sympathectomy 17/442 (3.8) 6/125 (4.8) 21/621 (3.4) 14/150 (9.3) 58/1338 (4.3)
Digital sympathectomy 8/441 (1.8) 0/125 (0.0) 14/619 (2.3) 6/148 (4.1) 28/1333 (2.1)
Arterial reconstruction 5/442 (1.1) 1/125 (0.8) 3/617 (0.5) 2/149 (1.3) 11/1333 (0.8)
Arthrodesis 5/388 (1.3) 3/106 (2.8) 12/539 (2.2) 6/124 (4.8) 26/1157 (2.2)
Debridement 22/384 (5.7) 6/106 (5.7) 68/537(12.7) 27/125 (21.6) 123/1152 (10.7)
Surgical amputation 23/390 (5.9) 7/106 (6.6) 54/542 (10.0) 20/126 (15.9) 104/1164 (8.9)
Use of parenteral prostanoids 223/439 (50.8) 70/127 (55.1) 394/608 (64.8) 113/150 (75.3) 800/1324 (60.4)
Number of DUs at enrolment, n 481 135 668 161 1445
0*, % 66.1 48.9 31.7 10.6 42.4
1–2, % 24.9 37.0 45.2 36.0 36.7
3+, % 8.9 14.1 23.1 53.4 20.9
Ongoing medication at enrolment, n 484 137 674 164 1459
Analgesics and anti-inflammatories, % 52.7 60.6 58.9 67.7 58.0
Immunosuppressants, % 37.0 34.3 31.8 34.8 34.1
Systemic antibiotics, % 6.0 13.9 18.8 27.4 15.1
ERA, any combination, % 41.5 38.7 49.6 46.3 45.5
Prostacyclins, % 27.1 28.5 42.1 43.3 36.0
CCB, % 43.6 41.6 47.5 53.7 46.3
PDE5i, % 4.8 4.4 6.1 4.9 5.3
ERA+PDE5i, % 2.1 2.2 1.5 1.2 1.7
ERA+prostacyclin, % 10.3 10.9 17.7 19.5 14.8
PDE5i+prostacyclin, % 0.6 0.0 2.5 2.4 1.6
Continued
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category contained the highest proportion of patients who
tested positive for anti-Scl-70 antibodies (60.4%), while the
lowest proportion was in the no-DU category (36.0%).
The highest use of analgesics/anti-inﬂammatories, systemic
antibiotics, calcium channel blockers and topical treatment for
DUs was observed in patients from the chronic category,
followed by recurrent, then episodic, and ﬁnally, no-DU (table 2).
At enrolment, patients from the recurrent and chronic categories
had the greatest proportion of previous DU-associated interven-
tions and complications (including hospitalisation, infections
requiring systemic antibiotics and amputation) (table 2).
During the 2-year period on which the deﬁnition was built,
the incidence of all analysed interventions and complications
increased across the categories. The incidence was lowest in the
no-DU category and highest in the chronic category (ﬁgure 1).
Patients in the chronic category experienced a ﬁrst new DU
earlier, followed by patients in the recurrent, episodic and
no-DU categories (ﬁgure 2).
The functional assessment questionnaire was completed by
34–59% of patients depending on the category (table 3).
Overall median work impairment due to DUs increased from
the no-DU to the chronic category (10% (no-DU), 10%
(episodic), 30% (recurrent) and 50% (chronic)). Median daily
activity impairment increased from 10% in the no-DU category
to 40% in the recurrent and 60% in the chronic categories. The
chronic category also recorded the highest proportion of
patients who needed help (66%) and the highest number of
hours needed for unpaid help (64 h). In contrast, only 16% of
patients in the no-DU category needed help, and, on average,
they only needed 11 h of unpaid help.
Identiﬁcation of predictive factors for developing
complications in the chronic category
Variables meeting a cut-off of p<0.15 in the ULR analysis (see
online supplementary table S2) were taken forward to MLR
analysis. The chronic category comprised these variables: GI
manifestations, presence of anti-U1-RNP antibodies, previous
soft tissue infection and ongoing soft tissue infection, both
requiring systemic antibiotics. The multivariable model (see
online supplementary table S3) showed GI manifestation
(p=0.03) and previous soft tissue infection (p=0.01) to be
independent predictive factors for developing incident compli-
cations in patients from the chronic category (OR 3.73, 95% CI
1.14 to 12.20, and 5.86, 95% CI 1.53 to 22.41, respectively).
The model excluded anti-U1-RNP due to the high level of
missing values in this variable.
Table 2 Continued
No-DU (n=484) Episodic (n=137) Recurrent (n=674) Chronic (n=164) Total (N=1459)
Other medications, % 74.8 73.7 71.7 63.4 72.0
Topical treatment of DUs at enrolment, n 484 137 674 164 1459
Any, % 7.6 15.3 24.8 34.8 19.3
Topical antibiotics, % 1.9 3.6 6.5 10.4 5.1
Proteolytic enzymes, % 0.8 0.0 1.2 3.0 1.2
Alginates, % 0.2 0.7 1.3 1.8 1.0
Growth factors, % 0.4 0.0 0.7 1.8 0.7
Dry dressing, % 4.1 6.6 10.8 13.4 8.5
Non-adhesive dressing, % 1.0 3.6 7.1 14.6 5.6
Hydro-colloids, % 2.3 5.1 7.4 12.8 6.1
Bioengineered skin, % 0.0 0.0 0.0 0.0 0.0
*All patients had prior DUs.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; CCB, calcium channel blocker; CTD, connective tissue disease; DUs, digital ulcers; ERA, endothelin receptor antagonist;
GI, gastrointestinal; n, n1, number of patients; n2, total number of patients for whom information was available; PDE5i, phosphodiesterase 5 inhibitor; RP, Raynaud’s phenomenon;
SSc, systemic sclerosis.
Figure 2 Time to ﬁrst new digital ulcer (DU) following enrolment.
Figure 1 Proportion of patients experiencing incident complications
or undergoing interventions over a 2-year observation period. *Pain
medication, n=483. †Soft tissue infection requiring antibiotics or
osteomyelitis. DU, digital ulcer.
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DISCUSSION
The present data conﬁrm that DUs are a signiﬁcant burden in
patients with SSc, and moreover, suggest that more severely
affected subgroups can be identiﬁed in clinical practice. This
analysis was performed in order to characterise and to under-
stand better the patterns of DU occurrence and disease
burden through the investigation of demographic and clinical
disease characteristics. Patients with recurrent or chronic DUs
showed a greater disease burden characterised by increased
incidence of complications, need for interventions and
impaired ability to function in their employment and daily
activities.
Why develop four categories?
There is a need to categorise patients in a way that enables
the physician to determine which groups of patients are
likely to have increased disease burden and thus need more
complex management. For example, Herrick et al10 classiﬁed
DUs according to their activity (active and inactive);
however, the inter-rater reliability for this grouping of
patients was poor. Another study categorised patients with
DUs according to DU origin and main features (pure DUs,
DUs derived from digital pitting scar, calcinosis or gan-
grene).11 Although the categorisation worked well, it charac-
terised patients according to type of DU rather than
according to disease burden. In the present study, four
patient categories were identiﬁed, based not on DU activity
but rather the timing of new ulcer development. The epi-
sodic, recurrent and chronic categories were deﬁned based
on the occurrence of DU events over the 2-year follow-up.
Hence, the no-DU category comprised patients with no DUs
over 2 years. We believe that these four categories better
reﬂect the level of disease burden associated with DUs and
may be useful in identifying groups of patients from a prog-
nostic perspective.
Identiﬁcation of patients with chronic DUs
Patients in the chronic category had the most severe clinical
characteristics and the most severe DU disease history. The
patients were younger at DU disease onset, which can have impli-
cations for their working life. When younger patients develop
chronic DUs, they are affected with a burdensome disease at a
phase of life when they need and/or want to maintain employ-
ment. Additionally, working life is affected for a longer time
period in young patients compared with older patients. Patients
in the chronic category had the highest proportion of GI manifes-
tations and pulmonary ﬁbrosis, again demonstrating the higher
disease burden for chronic patients. The pathogenesis of GI man-
ifestations has been linked to the vasculopathy that is a hallmark
of SSc,14 while increased frequency of pulmonary ﬁbrosis has
been previously observed in patients with DUs.15 Furthermore,
the chronic category contained the highest proportion of patients
on medications, the highest proportion of patients testing posi-
tive for anti-Scl-70 antibodies and with the most frequent history
of DU-associated interventions/complications. Scl-70 antibodies
are associated with more ﬁbrosis—skin,16 17 GI tract16 and
lung.17 18 Fewer patients in the chronic category were positive
for anticentromere antibodies compared with the other categor-
ies in contrast to a previous study19 that found that patients who
were positive for anticentromere antibodies were more likely to
have persistent and/or severe DUs.
DU disease burden during the 2-year observation period
Patients in the recurrent and chronic categories required the
most interventions (more hospitalisations, infections and pain
relief medication) and had the highest impairment in productiv-
ity and daily activity. They also had the greatest need for help,
reﬂected in the proportion who needed help and in the number
of hours of unpaid help received.
The higher occurrence of complications and/or interventions
in the recurrent and chronic categories may lead to a higher cost
Table 3 Functional assessment (N=670)
No-DU (n=185) Episodic (n=47) Recurrent (n=341) Chronic (n=97)
Work impairment, scale 0–10,* n 51 13 122 35
Mean 17.6 12.3 33.4 48.3
Median 10.0 0.0 30.0 50.0
95% CI of median 0.0 to 10.0 0.0 to 30.0 20.0 to 40.0 40.0 to 60.0
Overall work impairment,† n 51 13 122 35
Mean 19.0 14.1 35.5 50.6
Median 10.0 10.0 30.0 50.0
95% CI of median 0.0 to 20.0 0.0 to 30.0 20.0 to 40.0 40.0 to 60.0
Daily activity impairment, scale 0–10,* n 178 45 333 96
Mean 21.2 17.8 39.6 56.8
Median 10.0 0.0 40.0 60.0
95% CI of median 0.0 to 20.0 0.0 to 30.0 30.0 to 50.0 50.0 to 70.0
Help needed, n 184 46 338 97
Yes, n (%) 30 (16.3) 7 (15.2) 148 (43.8) 64 (66.0)
Hours of paid help, n 184 46 338 97
Mean 0.3 0.0 3.1 7.1
Hours of unpaid help, n 184 46 338 97
Mean 10.9 13.8 37.4 64.3
*Scale 0 (DU-associated problems had no effect) to 10 (DU-associated problems completely affected the patient’s ability to carry out that type of activity) transformed into percentage.
†Overall work impairment (expressed as percentage) calculated as the sum of work time missed and lost productivity at work (work time attended multiplied by work impairment
percentage).
DUs, digital ulcers; n, number of patients.
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of treatment in these patients. As survival improves,20 the
burden of disease and the potentially associated costs are
imperative to consider for planning disease management. It has
previously been shown that the costs of disease management are
higher in patients with DUs compared with patients without
DUs.21 These costs include both the direct costs such as hospital
stays, medication and payment for nurse procedures for treat-
ment of complications, but also indirect costs, such as absence
from work, lower productivity and an increased need for help
from others.
A recent publication from the EUSTAR cohort analysed the
characteristics, treatment patterns, healthcare resource utilisa-
tion, QoL and functional status of patients with newly diag-
nosed DUs from DU diagnosis to a prospective visit 3 months
after end of follow-up.22 Although this study did not categorise
patients in a similar manner to our study, in general, similar
rates of work and daily activity impairment were observed over
the observation period of 2.6 years. Daily activity impairment
was high, with half of patients with ≥1 DU at end of follow-up
requiring help for completion of daily activities, similar to the
recurrent and chronic categories of the current study. Of the
employed patients, overall work impairment was 35%.
DU-related complications were reported in 23% of patients, and
27% of patients required ≥1 DU procedure during follow-up.22
ULR and MLR analyses in chronic patients
In the chronic category, a logistic regression analysis was carried
out to identify those factors that may help predict which
patients may develop complications. Previous soft tissue
infection and GI manifestations present at enrolment were both
signiﬁcant predictive factors associated with incident complica-
tions. Consistent with the latter observations, GI manifestations
have previously been linked to increased risk of DUs in the
EUSTAR cohort of patients with SSc.23
STRENGTHS/LIMITATIONS
The large sample size and the prospective nature of data collec-
tion through 400 international centres, including some expert
centres, provided a broad sample of patients, thus allowing the
data to be generalisable to a wide patient population. However,
due to the nature of this registry, there may have been a
selection bias towards more severe patients as mainly centres
that prescribe bosentan were included as part of the EMA com-
mitment. It may have been difﬁcult for patients to assess and
quantify accurately their functioning during the recall period
(ie, the month before completing the questionnaire), and also to
separate the effects of DUs from those of the underlying SSc
when evaluating functioning.
CONCLUSION
This work used a unique and large prospective collection of DU
data to deﬁne a group with particularly severe DU disease that
have a high clinical burden of complications. Patients with
recurrent and chronic DUs experienced a higher disease burden
with an increased frequency of complications, more hospitalisa-
tions, greater impairment in functioning and an increased need
for help compared with patients with no DUs and episodic
DUs. The four categories proposed herein are complementary
to other groupings based on the origin of DUs (pure, calcinosis,
digital pitting scar, gangrene).11 The four categories show strik-
ing variation in clinical impact over time and are highly relevant
to clinical practice. Moreover, the categorisation may also have
an impact on the design of future clinical trials.
In summary, these four novel categories may better deﬁne
patients in the clinic with a high DU burden who might beneﬁt
from additional preventive therapy and consequently have
improvement in functioning and QoL.
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